DGAP-Adhoc: NanoRepro AG: Capital increase oversubscribed oversubscription

Not for publication, distribution, or distribution in or within the United States of America, Canada, Japan, and Australia

NanoRepro AG: Significant capital increase in IPO

Marburg, December 23, 2020. NanoRepro AG (symbol: NN6) has put in full cash capital increase announced on 27 November with subscription rights for shareholders. The underwriting of the capital increase was greatly exceeded.

As part of the capital increase, the company’s share capital will be increased by up to 2,640,000.00 € against cash contributions by issuing up to 2,640,000 new non-nominal bearer shares of value up to € 11,970,703.00. The new shares are entitled to a dividend from January 1, 2020.

The new shares were offered to shareholders of NanoRepro AG as part of an indirect subscription with a subscription ratio of 3.53: 1 from December 8 to 22, 2020 at 12 noon. 3.53 old shares entitle the holder to purchase a new share. In order to determine this subscription percentage, one of the shareholders agreed to waive the subscription right to an equivalent number of the old shares. The right to subscribe to fractional amounts has been excluded. During the subscription period, the shareholders were able to purchase the new shares at a subscription price of 3.03 euros per share.

The offering was intended only for the current shareholders of the company. The new shares that were not purchased by the shareholders under the legal right of subscription were offered to selected investors as part of a private placement with a subscription price of € 3.03 per new share. In total, approximately 50% of the shares were acquired from existing shareholders, and the remainder was issued to select investors as part of the private placement.

Net issue proceeds of approx. The 7.96 million euros will mainly be used to fund the primary and medium commodities for the rapid Corona tests. Additionally, NanoRepro plans to invest in scientific studies on the validity of rapid tests. In addition, more product innovations will be funded in the area of ​​”Corona Test”.

The new shares for trading on the stock exchange will be listed on the main board of the Frankfurt Stock Exchange after the implementation of the capital increase has been entered into the commercial registry.

call:
NanoRepro AG
www.nanorepro.com
Tel .: + 49-6421-951449
Email: juengst|@|nanorepro.com

Important instructions
This post does not constitute an offer or an invitation to buy or subscribe for securities in the United States of America (“United States of America”), Australia, Canada, Japan, or any other jurisdiction that is not permitted by law.
This publication and the information contained therein are for informational purposes only and do not constitute a prospectus, nor do they contain an offer to sell any securities in the United States of America or a solicitation of an offer to buy any securities in the United States of America. The securities referenced here have not been registered and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act”), or the laws of any state in the United States. Without this registration, they may not offer the securities, sell them, or transfer them in any other way, except for the securities offered and sold in accordance with an exemption from the registration requirements of the US Securities Act, which will be based on the prospectus if the securities are publicly offered in the United States which It will be approved by the US Securities and Exchange Commission (“SEC”) and available from the company, and contain detailed information about the company, its management and financial information. Neither the company nor any of its shareholders intend to register the securities referred to here in the United States. There is no public offering in the United States.

This publication does not constitute an offer to sell nor an invitation to buy any securities, as the offer is made exclusively on the basis of the securities information sheet to be published in Germany. The stock information sheet will also be available on the company’s website (www.nanorepro.com).

This document does not constitute an offer or offer for securities for the general public in the United Kingdom to which Section 85 of the UK Financial Services and Markets Act 2000 applies and is not intended to be a recommendation for any person to subscribe or purchase the securities in the context of the offer. This document is intended for redistribution only and is only intended for: (1) People outside the UK; (2) Persons with investment experience within the meaning of Section 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) in the United Kingdom 2005 (as amended) (the “Order”); Or (3) “High net worth companies, unregistered associations and other entities covered by Article 49 (2) (a) to (d) of the Ordinance (hereinafter referred to as“ Concerned Persons ”). Any person who is not a related person shall not be Acting on the basis of this advertisement or its contents, or reliance on it, any investment or investment activity related to this advertisement is available only to the persons concerned and will be implemented with them only.

Cautionary statement regarding forward-looking statements
This post contains forward-looking statements. These statements reflect the current beliefs, expectations and assumptions of the company’s management and are based on information currently available to the management. Forward-looking statements do not contain any guarantee of future results or developments and are related to known and unknown risks and uncertainties. Various factors, including changes in the general economic situation (including those resulting from the Corona epidemic), developments in financial markets, and other risks, particularly regarding the company and its business operations, can have an impact on the future results and developments of the company. It leads to the fact that actual future results and developments deviate significantly from the expectations and assumptions made here. The company assumes no obligation to update the data contained in this publication.